[go: up one dir, main page]

DE20005402U1 - External treatment for skin redness and psoriasis - Google Patents

External treatment for skin redness and psoriasis

Info

Publication number
DE20005402U1
DE20005402U1 DE20005402U DE20005402U DE20005402U1 DE 20005402 U1 DE20005402 U1 DE 20005402U1 DE 20005402 U DE20005402 U DE 20005402U DE 20005402 U DE20005402 U DE 20005402U DE 20005402 U1 DE20005402 U1 DE 20005402U1
Authority
DE
Germany
Prior art keywords
psoriasis
skin redness
cream
external treatment
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE20005402U
Other languages
German (de)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE20005402U priority Critical patent/DE20005402U1/en
Priority to DE20012104U priority patent/DE20012104U1/en
Publication of DE20005402U1 publication Critical patent/DE20005402U1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/30Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/52Juglandaceae (Walnut family)

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Description

sch &iacgr;&ogr; G 2sch &iacgr;&ogr; G 2

- &igr; - Keil&Schaafhausen- &igr; - Keil&Schaafhausen

PATENTANWÄLTEPATENT ATTORNEYS

Mittel zur äußerlichen Behandlung von SchuppenflechtenAgents for the external treatment of psoriasis

Gegenstand der Erfindung ist ein Mittel zur Behandlung von Hautrötungen und Schuppenflechten auf pflanzlicher Basis.The invention relates to a plant-based agent for the treatment of skin redness and psoriasis.

Die Schuppenflechte (Psoriasis) ist eine weit verbreitete Hautkrankheit. Ihre genaue Ursache ist nicht bekannt. Die Psoriasis wird polygen vererbt und tritt bei etwa 2 % der Bevölkerung in Erscheinung. Eine Vielzahl von Behandlungsmethoden stehen bereits zur Verfügung. So wirkt z. B. ein Teerbad mit anschließender UV-Bestrahlung antipsoriatisch. Auch eine Therapie nur mit lokalen Steroiden ist wirksam, führt aber aufgrund der langen Anwendung zu starken Nebenwirkungen und sollte deshalb zu Gunsten anderer Therapien 0 aufgegeben werden.Psoriasis is a widespread skin disease. Its exact cause is unknown. Psoriasis is inherited polygenically and occurs in about 2% of the population. A variety of treatment methods are already available. For example, a tar bath followed by UV radiation has an antipsoriatic effect. Therapy with local steroids alone is also effective, but leads to severe side effects due to the long-term use and should therefore be abandoned in favor of other therapies.

Es besteht deshalb weiterhin ein erheblicher Bedarf an einem gegen Psoriasis und die damit verbundenen Hautrötungen wirksamen Mittel, das frei von unerwünschten Nebenwirkungen 5 ist. Überraschenderweise hat sich gezeigt, dass ein gegen Psoriasis wirksames Heilmittel aus einem pflanzlichen Material gewonnen werden kann.There is therefore still a significant need for a remedy that is effective against psoriasis and the associated skin redness and that is free from undesirable side effects 5. Surprisingly, it has been shown that a remedy effective against psoriasis can be obtained from a plant material.

Gegenstand der Erfindung ist deshalb ein Mittel zur äußerlichen Behandlung von Hautrötungen und Schuppenflechten, das als Wirkstoff einen Extrakt aus Walnußkernen enthält. Es kann in Form einer Creme oder Salbe zur Verfügung gestellt werden.The invention therefore relates to a product for the external treatment of skin redness and psoriasis, which contains an extract from walnut kernels as an active ingredient. It can be made available in the form of a cream or ointment.

Diese besteht vorzugsweise aus einem Basiscreme, der einenThis preferably consists of a base cream that has a

Extrakt aus Walnußkernen enthält.
35
Contains extract from walnut kernels.
35

Sch 10 G 2 *.'".·.:·Sch 10 G 2 *.'".·.:·

- 2 - KEIL&SCHAAFHAUSEN- 2 - KEIL&SCHAAFHAUSEN

patentanwältepatent attorneys

Bisher sind nur die Blätter des Walnußbaumes arzneilich verwendet worden. Sie enthalten etwa 10 % Gerbstoffe, vor allem Juglon. Aufgrund des Gerbstoffgehaltes können Walnußblätter extern in Form von Bädern, Spülungen und Umschlägen bei Hautleiden wie Akne, Exzemen und Geschwüren angewendet werden. Innerlich werden Walnußblätter gelegentlich als Mittel gegen Durchfallerkrankungen eingesetzt. Eine arzneiliche Verwendung von Extrakten aus dem essbaren Teil der Walnuß, ihren Keimblättern, ist bisher nicht bekannt geworden.To date, only the leaves of the walnut tree have been used medicinally. They contain around 10% tannins, mainly juglone. Due to the tannin content, walnut leaves can be used externally in the form of baths, rinses and compresses for skin conditions such as acne, eczema and ulcers. Internally, walnut leaves are occasionally used as a remedy for diarrhea. There is no known medicinal use of extracts from the edible part of the walnut, its cotyledons.

Um so überraschender ist, dass ein Extrakt aus den stark ölhaltigen Walnußkeimblättern bemerkenswerte Wirksamkeit gegen die Schuppenflechte und die damit verbundenen Hautrötungen aufweist.It is all the more surprising that an extract from the highly oily walnut cotyledons has remarkable effectiveness against psoriasis and the associated skin redness.

Die erfindungsgemäße äußerliche Anwendung eines Extraktes aus Walnußkernen erfolgt vorzugsweise in Form einer Creme oder einer Salbe. Besonders bewährt hat sich die Herstellung einer Creme auf der Grundlage von Basiscremen, die selbst hergestellt oder auf dem Markt bezogen werden können, wie die Basiscreme 3013 der Firma Caesar & Lorentz GmbH, Hilden. Ein derartiger Basiscreme besteht aus Propylenglykol, weißer Vasiline, Sorbitol, einem Emulgator und Wasser.The external application of an extract from walnut kernels according to the invention is preferably carried out in the form of a cream or an ointment. The production of a cream based on base creams that can be made yourself or purchased on the market, such as the base cream 3013 from Caesar & Lorentz GmbH, Hilden, has proven particularly successful. Such a base cream consists of propylene glycol, white vaseline, sorbitol, an emulsifier and water.

Zur Herstellung der erfindungsgemäßen Creme werden Walnußkerne fein gemahlen. Dabei ist zu beachten, dass kein Öl austritt. Die gemahlenen Nüsse werden zusammen mit dem Basiscreme in ein Gefäß gegeben und auf 820C erwärmt. Bei dieser Temperatur sollte die Mischung 2 0 bis 3 0 Minuten gehalten werden. Die flüssige Masse wird während dieser Zeit mit einem Rührwerk (45 0 RPM) umgerührt. Anschließend werden die geschnittenen Nußkerne mit Hilfe eines Siebes, das zum Beispiel eine Maschenweite von 0,2 mm aufweisen kann, abgeseit. Die noch flüssige Creme wird dann sofort mit Hilfe einer Vakuumpumpe in Tuben oder Salbenkruken luftfrei abgefüllt. Diese BehälterTo produce the cream according to the invention, walnut kernels are finely ground. Care must be taken to ensure that no oil escapes. The ground nuts are placed in a container together with the base cream and heated to 82 0 C. The mixture should be kept at this temperature for 2 0 to 3 0 minutes. During this time, the liquid mass is stirred with a stirrer (45 0 RPM). The cut walnut kernels are then strained using a sieve, which can have a mesh size of 0.2 mm, for example. The still liquid cream is then immediately filled into tubes or ointment jars without any air using a vacuum pump. These containers

16.03.0016.03.00

sch &iacgr;&ogr; G 2 .· ,· · i .* : :: :sch &iacgr;&ogr; G 2 .· ,· · i .* : :: :

- 3 - KEIL&SCHAAFHAUSEN- 3 - KEIL&SCHAAFHAUSEN

PATENTANWÄLTEPATENT ATTORNEYS

sollten bis zum Rand gefüllt werden. Die Creme ist dann sofort mit einer Folie abzudecken und die Behälter zu verschließen, um oxidative Einwirkungen durch Luft oder Sauerstoff zu vermeiden. Im abgekühlten Zustand ist die Creme dann gebrauchsfertig. should be filled to the brim. The cream should then be immediately covered with foil and the containers closed to avoid oxidative effects from air or oxygen. Once cooled, the cream is ready for use.

Zur Behandlung der mit Schuppenflechten oder Hautrötungen befallenen Hautpartien empfiehlt es sich, das erfindungsgemäße Mittel mehrmals täglich aufzutragen und einwirken zu lassen. Schon nach einer Behandlungsdauer von 2 bis 3 Wochen zeigt sich in der Regel eine erhebliche Verbesserung der Hauterkrankung, die zur vollständigen Beseitigung der Schuppenflechte und der Hautrötungen führt, wenn die Behandlung über 6 bis 8 Wochen fortgesetzt wird.To treat the skin areas affected by psoriasis or skin redness, it is recommended to apply the agent according to the invention several times a day and allow it to take effect. After just 2 to 3 weeks of treatment, there is usually a significant improvement in the skin condition, which leads to the complete elimination of psoriasis and skin redness if the treatment is continued for 6 to 8 weeks.

16.03.00 · ··16.03.00 · ··

Claims (3)

1. Mittel zur äußerlichen Behandlung von Hautrötungen und Schuppenflechten, dadurch gekennzeichnet, dass es als Wirkstoff einen Extrakt aus Walnusskernen enthält. 1. Agent for the external treatment of skin redness and psoriasis, characterized in that it contains an extract of walnut kernels as the active ingredient. 2. Mittel nach Anspruch 1, dadurch gekennzeichnet, dass es in Form einer Creme oder einer Salbe vorliegt. 2. Agent according to claim 1, characterized in that it is in the form of a cream or an ointment. 3. Mittel nach Anspruch 2, dadurch gekennzeichnet, dass es aus einem Basiscreme besteht, der einen Extrakt aus Walnußkernen enthält. 3. Agent according to claim 2, characterized in that it consists of a base cream which contains an extract of walnut kernels.
DE20005402U 2000-03-22 2000-03-22 External treatment for skin redness and psoriasis Expired - Lifetime DE20005402U1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE20005402U DE20005402U1 (en) 2000-03-22 2000-03-22 External treatment for skin redness and psoriasis
DE20012104U DE20012104U1 (en) 2000-03-22 2000-07-12 External treatment for pain, reddening of the skin, psoriasis and neurodermatitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE20005402U DE20005402U1 (en) 2000-03-22 2000-03-22 External treatment for skin redness and psoriasis

Publications (1)

Publication Number Publication Date
DE20005402U1 true DE20005402U1 (en) 2000-07-20

Family

ID=7939229

Family Applications (2)

Application Number Title Priority Date Filing Date
DE20005402U Expired - Lifetime DE20005402U1 (en) 2000-03-22 2000-03-22 External treatment for skin redness and psoriasis
DE20012104U Expired - Lifetime DE20012104U1 (en) 2000-03-22 2000-07-12 External treatment for pain, reddening of the skin, psoriasis and neurodermatitis

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE20012104U Expired - Lifetime DE20012104U1 (en) 2000-03-22 2000-07-12 External treatment for pain, reddening of the skin, psoriasis and neurodermatitis

Country Status (1)

Country Link
DE (2) DE20005402U1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009860A1 (en) * 2001-07-07 2003-02-06 Lore Klett-Loch Gdbr Preparation used for the topical treatment of pains and skin diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626529A (en) 1981-10-23 1986-12-02 L'oreal Oily compositions comprising a dermatological active principle, intended for the treatment of the scalp or skin
DE4021082A1 (en) 1990-07-03 1992-01-23 Hans Dr Lautenschlaeger Skin care product with high lipid content - contains a bi:layer source, salts of organic acids, alcohol, stabiliser and lipid(s)
DE19654468C1 (en) 1996-12-27 1998-01-22 Lohmann Therapie Syst Lts Flexible dermal or transdermal plaster for drug or cosmetic release
DE19831798A1 (en) 1998-07-15 2000-01-27 Mandorlo Investment Gmbh Luxem Microcirculation improving skin and tissue care or treatment composition, containing salts, aminoacids and peroxide, used as cosmetic, medicament or nutrient supplement

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626529A (en) 1981-10-23 1986-12-02 L'oreal Oily compositions comprising a dermatological active principle, intended for the treatment of the scalp or skin
DE4021082A1 (en) 1990-07-03 1992-01-23 Hans Dr Lautenschlaeger Skin care product with high lipid content - contains a bi:layer source, salts of organic acids, alcohol, stabiliser and lipid(s)
DE19654468C1 (en) 1996-12-27 1998-01-22 Lohmann Therapie Syst Lts Flexible dermal or transdermal plaster for drug or cosmetic release
DE19831798A1 (en) 1998-07-15 2000-01-27 Mandorlo Investment Gmbh Luxem Microcirculation improving skin and tissue care or treatment composition, containing salts, aminoacids and peroxide, used as cosmetic, medicament or nutrient supplement

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009860A1 (en) * 2001-07-07 2003-02-06 Lore Klett-Loch Gdbr Preparation used for the topical treatment of pains and skin diseases

Also Published As

Publication number Publication date
DE20012104U1 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
AT406731B (en) SUBSTANCE MIXTURE FOR TOPICAL APPLICATION
DD277210A5 (en) THERAPEUTIC COMPOSITIONS AGAINST PSORIASIS
EP0345571A1 (en) Plant extract composition for cosmetical use
CH666618A5 (en) Skin regenerating cosmetic compsns.
EP0668768B1 (en) Composition for controlling dermatomycoses and their agents, as well as transpiration and bodily odours
DE20005402U1 (en) External treatment for skin redness and psoriasis
EP0355149B1 (en) Herbal tea composition and process for producing it
CH682631A5 (en) Herbal compsns. for promoting hair growth - contain nettle, pansy and chickweed
DE68906205T2 (en) COSMETIC AND PARAMEDICAL PREPARATIONS.
EP0384308B1 (en) Extract medicament
DE3519736C2 (en) Agents for the treatment of rheumatism and polyarthritis
DE202014005062U1 (en) elixir
CH492593A (en) Skin care products
EP1455806B1 (en) Active agent mixture containing a plant extract of convolvulaceae for treating hair problems, skin disorders and skin diseases
DE3915535A1 (en) Compsns. for treating skin disorders - contain trigonellin or trigonellic acid
DE4237551C1 (en) Use of a plant-based composition to combat dermatomycoses
AT381449B (en) METHOD FOR PRODUCING A HAIR GROWING AGENT
DE19910697C2 (en) Process for the preparation of a therapeutically active substance and use thereof
DE19916935A1 (en) Cosmetic or dermatological composition useful for treating the skin and/or hair of humans or animals comprises honey, olive oil and lemon juice
DE3901575C2 (en)
EP2842543B1 (en) Composition with cooling effect for topical application
DE3930849A1 (en) Pharmaceutical prepn. obtd. from specific citrus species - used to treat gastrointestinal disorders, esp. diarrhoea
EP1530971A1 (en) Composition for the treatment of tooth and gum diseases
DE4212057C2 (en) Preparation consisting of a solution of oleander leaves in petroleum
DE102007040025A1 (en) Hair restorer, useful e.g. for external application on skin and as shampoo, conditioner, hair tonic and lotion, comprises component of aqueous extract of bulbous plant (Alliaceae) and/or bulbous plant oil

Legal Events

Date Code Title Description
R207 Utility model specification

Effective date: 20000824

R163 Identified publications notified

Effective date: 20001219

R150 Utility model maintained after payment of first maintenance fee after three years

Effective date: 20030411

R157 Lapse of ip right after 6 years

Effective date: 20061003